NeurAxis, Inc. (NRXS)
Automate Your Wheel Strategy on NRXS
With Tiblio's Option Bot, you can configure your own wheel strategy including NRXS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NRXS
- Rev/Share 0.3776
- Book/Share 0.4992
- PB 6.2903
- Debt/Equity 0.0448
- CurrentRatio 2.8197
- ROIC -1.426
- MktCap 30978172.0
- FreeCF/Share -0.7337
- PFCF -4.9551
- PE -3.7303
- Debt/Assets 0.0269
- DivYield 0
- ROE -5.9949
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
NeurAxis Stock Down Following Q2 Earnings Despite Revenue Growth
Published: August 18, 2025 by: Zacks Investment Research
Sentiment: Negative
NRXS reports strong second-quarter 2025 revenue growth and lower losses, but gross margin compression remains a key concern.
Read More
NeurAxis, Inc. (NRXS) Q2 2025 Earnings Call Transcript
Published: August 12, 2025 by: Seeking Alpha
Sentiment: Neutral
NeurAxis, Inc. (NYSE:NRXS ) Q2 2025 Earnings Conference Call August 12, 2025 9:00 AM ET Company Participants Brian Carrico - President, CEO & Director Timothy Robert Henrichs - Chief Financial Officer Conference Call Participants Ben Shamsian - Unidentified Company Chase Richard Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Lindsay Leeds - Unidentified Company Operator Good day, everyone, and welcome to the NeurAxis Report Second Quarter 2025 Financial Results. [Operator Instructions] Please note that this conference is being recorded.
Read More
NeurAxis Announces Closing of $5.0 Million Registered Direct Offering
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
CARMEL, Ind., May 22, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced the closing of its previously announced registered direct offering of 1,538,461 shares of its common stock at a purchase price of $3.25 per share.
Read More
NeurAxis Stock Gains Following Strong Q1 Earnings and FDA Milestones
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive
NRXS posts strong first-quarter 2025 earnings with robust revenue growth and FDA milestones, driving stock gains as investors eye broader insurance coverage and market expansion.
Read More
NeurAxis, Inc. (NRXS) Q1 2025 Earnings Call Transcript
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Neutral
NeurAxis, Inc. (NYSE:NRXS ) Q1 2025 Earnings Conference Call May 12, 2025 9:00 AM ET Company Participants Ben Shamsian - IR Brian Carrico - President, CEO & Director Tim Henrichs - CFO Brian Carrico - President, CEO & Director Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the NeurAxis First Quarter 2025 Results and Update Call.
Read More
NeurAxis Reports Strong First Quarter 2025 Financial Results Driven by a 39% Growth in Revenues
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
CARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the first quarter 2025 for the period ended March 31, 2025.
Read More
NeurAxis to Host Fourth Quarter and Full Year 2024 Results and Business Update Call on Thursday, March 20, 2025
Published: March 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
CARMEL, Ind., March 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its fourth quarter and fiscal year 2024, for the period ended December 31, 2024, on Thursday, March 20, 2025, before market open. The Company has scheduled a conference call for the same day, Thursday, March 20, 2025, at 9:00 am ET to review the results.
Read More
About NeurAxis, Inc. (NRXS)
- IPO Date 2023-08-09
- Website https://neuraxis.com
- Industry Biotechnology
- CEO Brian Carrico
- Employees 21